The label expansion may improve insurance coverage for Wegovy, which costs more than $1,300 per month out of pocket before any discounts.
Many insurers, including Medicare, don’t cover drugs for weight loss, leaving patients scrambling to afford them.
“This patient population has a higher risk of cardiovascular death, heart attack and stroke,” he added.
More studies need to be done to show whether there are heart benefits for people who haven’t had a cardiac event.
Wegovy continues to be in shortage, along with other GLP-1 medicines, as drugmakers struggle to keep up with demand.
Persons:
CNN — Wegovy’s, –, Dr, Harlan Krumholz, hasn’t, Eli Lilly, Wegovy, John Sharretts, haven’t, it’s, Sanjay Gupta, Jody Dushay, Beth, Dushay, Novo, Doug Langa, ”
Organizations:
CNN, US Food and Drug Administration, Yale University, Yale New Haven Hospital, Novo Nordisk, Diabetes, ”, CNN Health, Beth Israel Deaconess Medical Center, Harvard Medical School, Novo Nordisk’s, North America Operations